The same tumour also displays a loss of heterozygosity (LOH) in the APC. The breast cancer NST displays many alternations, including a loss of BRCA2 but no loss of APC. The therapy-associated myeloproliferative neoplasia of the primary myelofibrosis type does not show any significant alterations. The gene discussed is BRCA2; the disease is breast carcinoma.